Your browser is no longer supported. Please, upgrade your browser.
MyMD Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.17 Insider Own2.20% Shs Outstand37.14M Perf Week5.05%
Market Cap162.32M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float32.14M Perf Month22.79%
Income-10.10M PEG- EPS next Q- Inst Own3.20% Short Float3.85% Perf Quarter-34.76%
Sales- P/S- EPS this Y68.80% Inst Trans5.49% Short Ratio3.03 Perf Half Y15.66%
Book/sh3.89 P/B1.18 EPS next Y- ROA- Target Price- Perf Year-31.64%
Cash/sh0.88 P/C5.22 EPS next 5Y- ROE- 52W Range3.30 - 13.94 Perf YTD15.08%
Dividend- P/FCF- EPS past 5Y65.40% ROI- 52W High-67.14% Beta0.25
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low38.79% ATR0.33
Employees4 Current Ratio14.40 Sales Q/Q- Oper. Margin- RSI (14)54.73 Volatility6.41% 8.64%
OptionableYes Debt/Eq0.00 EPS Q/Q94.70% Profit Margin- Rel Volume0.16 Prev Close4.44
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume407.81K Price4.58
Recom- SMA208.62% SMA50-2.68% SMA200-8.29% Volume64,267 Change3.15%
Jun-07-21 10:02AM  
May-17-21 09:00AM  
May-12-21 09:00AM  
May-10-21 09:00AM  
Apr-28-21 10:13AM  
Apr-22-21 09:20AM  
MyMD Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the development of drug products in the targeting of aging and age-related diseases; autoimmune diseases; and chronic pain, anxiety, and sleep disorders. It commercializes MYMD-1, a novel therapeutic to impact conditions related to immunometabolic dysregulation; and SUPERA-1R, a synthetic cannabidiol that offers bioavailability and potency than botanicals. The company was incorporated in 2014 and is based in Tampa, Florida.